NEONasdaqServices-Testing LaboratoriesFiscal year ends December 31
NEOGENOMICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026
$16.42−0.23 (-1.38%)
Close on Oct 19, 2026
- Market cap
- $2.15B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
43.2%+1.4 pts over 5 years
Operating margin
-15.9%−12.8 pts over 5 years
Net margin
-14.9%−15.8 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +10.1% | +12.6% | +10.4% | +22.0% | |
| Gross profit | +8.3% | +18.7% | +11.1% | +21.8% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -3.3% | 0.7% | -12.4% | |
| Return on assets | -1.8% | 0.5% | -7.2% | |
| Current ratio | 2.07 | 6.13 | 4.26 | |
| Debt to equity | 0.65 | 0.24 | 0.41 | |
| Net debt to EBITDA | 5.18× | -6.85× | – | |
| Interest coverage | – | -2.0× | -30.9× | |
| Inventory turnover | 23.5× | 11.8× | 14.9× | |
| Capex to revenue | 3.3% | 6.5% | 3.7% | |
| Diluted shares | 78M | 112M | 128M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Neogenomics generated $106.92M from operations and spent $191.85M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$106.92M
Used
$191.85M
Capital expenditure$191.85M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-14.9%
×Asset turnover0.49×
×Equity multiplier1.72×
=Return on equity, FY2025-12.4%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -14.9% | 0.49× | 1.72× | -12.4% |
| FY2024 | -11.9% | 0.40× | 1.80× | -8.5% |
| FY2023 | -14.9% | 0.35× | 1.76× | -9.1% |
| FY2022 | -28.3% | 0.28× | 1.71× | -13.7% |
| FY2021 | -1.7% | 0.34× | 1.59× | -0.9% |
| FY2020 | 0.9% | 0.52× | 1.41× | 0.7% |
| FY2019 | 2.0% | 0.67× | 1.47× | 1.9% |
| FY2018 | 1.0% | 0.65× | 1.73× | 1.1% |
| FY2017 | -0.2% | 0.70× | 2.04× | -0.2% |
| FY2016 | -2.6% | 0.67× | 1.86× | -3.3% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$108.03M
- Cash generatingOperating cash flow above zero$5.23M
- Return on assets improvedROA up on the prior year-4.7% → -6.6%
- Earnings backed by cashOperating cash flow above net income$5.23M vs -$108.03M
- Less leverageLong-term debt to assets fell20.8% → 25.1%
- Better liquidityCurrent ratio rose1.98 → 4.26
- No dilutionShare count did not rise127M → 128M
- Gross margin improvedGross margin up on the prior year43.92% → 43.21%
- More efficientAsset turnover rose0.39 → 0.44